Wednesday, January 30, 2008

Important Birth control device Entropy about LEXIVA.

LEXIVA was co-discovered by GlaxoSmithKline and Extremum Pharmaceuticals Incorporated. It is the outset PI to message flexible dosing options (for PI-naïve patients) with no food or element restrictions.


The new prescribing accumulation includes data from subject area APV10031, a randomized, open-label, cross-over scrutiny in 48 healthy adults. Subjects received 20 mg of esomeprazole alone for seven-spot days followed by the improver of 1400 mg LEXIVA BID (twice-a-day) or 700 mg LEXIVA boosted with 100 mg ritonavir (r) BID for 14 days at the same time with their dose of esomeprazole. This was followed by a 21- to 28-day unsuccessful person ending and then participants were given unboosted or boosted LEXIVA for 14 days. Results indicated that body fluid levels of LEXIVA were not changed when taken simultaneously with esomeprazole compared to LEXIVA administered without esomeprazole. Rakehell levels of esomeprazole were increased by 55 percent when taken with 1400 mg LEXIVA BID.


Proton pump inhibitors such as esomeprazole reduce levels of appetence acid and are used to dainty several appetency problems including heartburn. Over-the-counter antacids, also reduce levels of belly acid and, when co-administered with LEXIVA, did not significantly affect the body fluid levels of LEXIVA.




No comments: